G1 Therapeutics Inc Stock News

G1 Therapeutics Inc (GTHX) shares closed today at 0.2% above its 52 week low of $9.65, giving the company a market cap of $421M. The stock is currently down 2.8% year-to-date, down 43.6% over the past 12 months, and down 33.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 14.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 5.1% lower than its 5-day moving average, 8.0% lower than its 20-day moving average, and 26.3% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1053.0% The company's stock price performance over the past 12 months lags the peer average by 513.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two up

RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerc

- G1 and Boehringer Ingelheim Mutually Agree to End Co-Promotion Agreement -

- G1 and Boehringer Ingelheim Mutually Agree to End Co-Promotion Agreement -

Wall Street brokerages predict that G1 Therapeutics, Inc. (NASDAQ:GTHX) will announce sales of $5.58 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for G1 Therapeutics earnings. The lowest sales estimate is $5.20 million and the highest is $6.71 million. G1 Therapeutics posted sales of $16.55 million during []

Equities analysts expect G1 Therapeutics, Inc. (NASDAQ:GTHX) to post $5.58 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for G1 Therapeutics earnings, with the highest sales estimate coming in at $6.71 million and the lowest estimate coming in at $5.20 million. G1 Therapeutics reported sales []

Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) have earned an average rating of “Buy” from the seven analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 1-year price […]

G1 Therapeutics, Inc. (NASDAQ:GTHX)s stock price hit a new 52-week low during trading on Thursday . The company traded as low as $11.91 and last traded at $11.98, with a volume of 26335 shares trading hands. The stock had previously closed at $12.51. A number of research analysts have recently issued reports on GTHX shares. []

RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerc

New Trial Designed to Further Investigate the Immune-Based MOA of Trilaciclib and Help Determine Future Target Tumor Types and Treatment Combinations New Trial Designed to Further Investigate the Immu

New Trial Designed to Further Investigate the Immune-Based MOA of Trilaciclib and Help Determine Future Target Tumor Types and Treatment Combinations New Trial Designed to Further Investigate the Immune-Based MOA of Trilaciclib and Help Determine Future Target Tumor Types and Treatment Combinations

Trial Will Evaluate Anti-Tumor Efficacy and Myeloprotection Endpoints in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) Trial Will Evaluate Anti-Tumor E

Trial Will Evaluate Anti-Tumor Efficacy and Myeloprotection Endpoints in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) Trial Will Evaluate Anti-Tumor Efficacy and Myeloprotection Endpoints in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)

Credit Suisse AG cut its holdings in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) by 11.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,378 shares of the companys stock after selling 2,644 shares during the period. Credit Suisse AGs [] The post Credit Suisse AG Sells 2,644 Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) appeared first on ETF Daily News .